Ahmed Alaa Kassem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed Alaa Kassem has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Sameh Hosam Abd El-Alim
Pharmaceutical Technology Department, National Research Centre, Cairo, Egypt
12 shared publications - Marwa Hasanein Asfour
Pharmaceutical Technology Department, National Research Centre, El-Buhouth St., Dokki, Cairo 12622, Egypt
8 shared publications Abeer Salama
Pharmacology Department, National Research Centre, El- Buhouth St., Dokki, Cairo 12622, Egypt
7 shared publications- Dina Mahmoud Mostafa
Pharmaceutical Technology Department, National Research Centre, Cairo, Egypt
5 shared publications - Abeer Salama
Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 12622, Egypt
4 shared publications - Mona Basha
Pharmaceutical Technology Department, National Research Centre, Cairo 12622, Egypt
4 shared publications
Latest Publications
- Open Access
- 26 June 2025
- Published by Elsevier in LabMed Discovery
- Vol. 2 (2)
Improved core manifestations of autism following supplementation with vitamin D3-loaded nanoemulsion
- 26 June 2025
- Published by Elsevier in LabMed Discovery
- Vol. 2 (2)
Open AccessImproved core manifestations of autism following supplementation with vitamin D3-loaded nanoemulsion
- Open Access
- 9 February 2023
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 24 (2) , 1-14
Vitamin D3-Loaded Nanoemulsions as a Potential Drug Delivery System for Autistic Children: Formulation Development, Safety, and Pharmacokinetic Studies
The aim of the current study is the development of a vitamin D3 (VD3)-loaded nanoemulsion (NE) formulation to improve VD3 oral bioavailability for management of vitamin D inadequacy in autistic children. Eight NE formulations were prepared by high-speed homogenization followed by ultrasonication. Four vegetable oils were employed along with two concentrations of Span 20 as the emulsifier. Glycerol, fructose, and mango flavor were included as viscosity modifier, sweetening, and flavoring agents, respectively. The prepared VD3-loaded NE formulations exhibited high drug content (> 98%), droplet size (DS) ranging from 61.15 to 129.8 nm with narrow size distribution, zeta potential values between − 9.83 and − 19.22 mV, and acceptable pH values (4.59–5.89). Storage stability showed that NE formulations underwent coalescence and phase separation during 6 months at room temperature, whereas at refrigerated conditions, formulations showed slight creaming. The optimum formulation (VD3-NE6) revealed a non-significant DS growth at refrigerated conditions and spherical morphology under transmission electron microscopy. VD3-NE6 did not produce any toxic effects to rats treated orally for 3 months, where normal blood picture and kidney and liver functions were observed compared to control rats. Also, serum calcium, oxidative stress, and apoptosis biomarkers remained within normal levels, indicating the safety of the optimum formulation. Furthermore, evaluation of VD3-NE6 oral bioavailability depicted a significant increase in AUC0–72 and Cmax with decreased Tmax compared to plain VD3. The optimum formulation demonstrated improved stability, safety, and oral bioavailability indicating the potential for successful management of vitamin D deficiency in autistic children.
- 9 February 2023
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 24 (2) , 1-14
Open AccessVitamin D3-Loaded Nanoemulsions as a Potential Drug Delivery System for Autistic Children: Formulation Development, Safety, and Pharmacokinetic Studies
The aim of the current study is the development of a vitamin D3 (VD3)-loaded nanoemulsion (NE) formulation to improve VD3 oral bioavailability for management of vitamin D inadequacy in autistic children. Eight NE formulations were prepared by high-speed homogenization followed by ultrasonication. Four vegetable oils were employed along with two concentrations of Span 20 as the emulsifier. Glycerol, fructose, and mango flavor were included as viscosity modifier, sweetening, and flavoring agents, respectively. The prepared VD3-loaded NE formulations exhibited high drug content (> 98%), droplet size (DS) ranging from 61.15 to 129.8 nm with narrow size distribution, zeta potential values between − 9.83 and − 19.22 mV, and acceptable pH values (4.59–5.89). Storage stability showed that NE formulations underwent coalescence and phase separation during 6 months at room temperature, whereas at refrigerated conditions, formulations showed slight creaming. The optimum formulation (VD3-NE6) revealed a non-significant DS growth at refrigerated conditions and spherical morphology under transmission electron microscopy. VD3-NE6 did not produce any toxic effects to rats treated orally for 3 months, where normal blood picture and kidney and liver functions were observed compared to control rats. Also, serum calcium, oxidative stress, and apoptosis biomarkers remained within normal levels, indicating the safety of the optimum formulation. Furthermore, evaluation of VD3-NE6 oral bioavailability depicted a significant increase in AUC0–72 and Cmax with decreased Tmax compared to plain VD3. The optimum formulation demonstrated improved stability, safety, and oral bioavailability indicating the potential for successful management of vitamin D deficiency in autistic children.
- 2 January 2023
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 28 (1) , 109-123
Chrysin–phospholipid complex-based solid dispersion for improved anti-aging and neuroprotective effects in mice
The present study aimed to improve the neuroprotective effect of chrysin (CHR) by combining two formulation techniques, phospholipid complexation and solid dispersion (SD). CHR-phospholipid complex (CHR-PLC) was prepared through solvent evaporation. The molar ratio CHR/PL (1:3), which exhibited the highest complexation efficiency, was selected for the preparation of CHR-PLC loaded SD (CHR-PLC-SD) with 2-hydroxypropyl β cyclodextrin (2-HPβCD) and polyvinylpyrrolidone 8000. CHR-PLC/2-HPβCD (1:2, w/w) displayed the highest aqueous solubility of CHR (5.86 times more than that of plain CHR). CHR-SD was also prepared using 2-HPβCD for comparison. The in vitro dissolution of CHR-PLC-SD revealed an enhancement in the dissolution rate over CHR-PLC, CHR-SD, and plain CHR by six times. The optimum formulations and plain CHR were evaluated for their neuroprotective effect on brain aging induced by D-galactose in mice. The results demonstrated a behavioral activity elevation, an increase of AMPK, LKB1, and PGC1α brain contents as well as a reduction of AGEs, GFAP, NT-3, TNF-α, and NF-κβ brain contents when compared with those in the D-galactose control group. Thus, the developed formulations stimulated neurogenesis and mitochondrial biogenesis as well as suppressed neuroinflammation and neurodegeneration. The order of activity was as follows: CHR-PLC-SD4 > CHR-PLC (1:3) > CHR-SD > plain CHR. Graphical Abstract
- 2 January 2023
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 28 (1) , 109-123
Chrysin–phospholipid complex-based solid dispersion for improved anti-aging and neuroprotective effects in mice
The present study aimed to improve the neuroprotective effect of chrysin (CHR) by combining two formulation techniques, phospholipid complexation and solid dispersion (SD). CHR-phospholipid complex (CHR-PLC) was prepared through solvent evaporation. The molar ratio CHR/PL (1:3), which exhibited the highest complexation efficiency, was selected for the preparation of CHR-PLC loaded SD (CHR-PLC-SD) with 2-hydroxypropyl β cyclodextrin (2-HPβCD) and polyvinylpyrrolidone 8000. CHR-PLC/2-HPβCD (1:2, w/w) displayed the highest aqueous solubility of CHR (5.86 times more than that of plain CHR). CHR-SD was also prepared using 2-HPβCD for comparison. The in vitro dissolution of CHR-PLC-SD revealed an enhancement in the dissolution rate over CHR-PLC, CHR-SD, and plain CHR by six times. The optimum formulations and plain CHR were evaluated for their neuroprotective effect on brain aging induced by D-galactose in mice. The results demonstrated a behavioral activity elevation, an increase of AMPK, LKB1, and PGC1α brain contents as well as a reduction of AGEs, GFAP, NT-3, TNF-α, and NF-κβ brain contents when compared with those in the D-galactose control group. Thus, the developed formulations stimulated neurogenesis and mitochondrial biogenesis as well as suppressed neuroinflammation and neurodegeneration. The order of activity was as follows: CHR-PLC-SD4 > CHR-PLC (1:3) > CHR-SD > plain CHR. Graphical Abstract
- 26 August 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (10) , 1589-1603
Improved hepatoprotective activity of Beta vulgaris L. leaf extract loaded self-nanoemulsifying drug delivery system (SNEDDS): in vitro and in vivo evaluation
Objective: Beta vulgaris L. (beetroot) is a vegetable plant rich in phytochemical compounds such as phenolic acids, carotenoids and flavonoids. The objective of the current study is the development and optimization of self-nanoemulsifying drug delivery systems (SNEDDSs) to enhance the hepatoprotective activity of beet leaf (BL) extract. Methods: Total flavonoids content was estimated in the BL extract and its solubility was evaluated in various vehicles to select proper component combinations. Pseudo-ternary phase diagrams were constructed employing olive, linseed, castor and sesame oils (oil phase), Tween® 20 (Tw20) and Tween® 80 (Tw80) (surfactants) as well as dimethyl sulfoxide (DMSO) and propylene glycol (PG) (co-surfactants). Optimization of formulations from the phase diagrams took place through testing their thermodynamic stability, dispersibility and robustness to dilution. Results: Four optimized BL-SNEDDS formulations, comprising linseed and olive oils, Tw80 and DMSO at surfactant/co-surfactant ratios (2:1 or 3:1) were chosen. They exhibited high cloud point and percentage transmittance values with spherical morphology of mean droplet sizes ranging from 14.67 to 16.06 nm and monodisperse distribution with negatively charged zeta potential < −9.51 mV. The in vitro release profiles of the optimized formulations in pH 1.2 and 6.8 were nearly similar, with a non-Fickian release mechanism. In vivo evaluation of BL-SNEDDSs hepatoprotective activity in a thioacetamide-induced hepatotoxicity rat model depicted promoted liver functions, inflammatory markers and histopathological findings, most prominently in the group treated by F7. Conclusion: The results indicate that SNEDDS as a nanocarrier system has potential to improve the hepatoprotective activity of the BL extract.
- 26 August 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (10) , 1589-1603
Improved hepatoprotective activity of Beta vulgaris L. leaf extract loaded self-nanoemulsifying drug delivery system (SNEDDS): in vitro and in vivo evaluation
Objective: Beta vulgaris L. (beetroot) is a vegetable plant rich in phytochemical compounds such as phenolic acids, carotenoids and flavonoids. The objective of the current study is the development and optimization of self-nanoemulsifying drug delivery systems (SNEDDSs) to enhance the hepatoprotective activity of beet leaf (BL) extract. Methods: Total flavonoids content was estimated in the BL extract and its solubility was evaluated in various vehicles to select proper component combinations. Pseudo-ternary phase diagrams were constructed employing olive, linseed, castor and sesame oils (oil phase), Tween® 20 (Tw20) and Tween® 80 (Tw80) (surfactants) as well as dimethyl sulfoxide (DMSO) and propylene glycol (PG) (co-surfactants). Optimization of formulations from the phase diagrams took place through testing their thermodynamic stability, dispersibility and robustness to dilution. Results: Four optimized BL-SNEDDS formulations, comprising linseed and olive oils, Tw80 and DMSO at surfactant/co-surfactant ratios (2:1 or 3:1) were chosen. They exhibited high cloud point and percentage transmittance values with spherical morphology of mean droplet sizes ranging from 14.67 to 16.06 nm and monodisperse distribution with negatively charged zeta potential < −9.51 mV. The in vitro release profiles of the optimized formulations in pH 1.2 and 6.8 were nearly similar, with a non-Fickian release mechanism. In vivo evaluation of BL-SNEDDSs hepatoprotective activity in a thioacetamide-induced hepatotoxicity rat model depicted promoted liver functions, inflammatory markers and histopathological findings, most prominently in the group treated by F7. Conclusion: The results indicate that SNEDDS as a nanocarrier system has potential to improve the hepatoprotective activity of the BL extract.
- 7 May 2020
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 37 (5) , 366-383
Development of folic acid–loaded nanostructured lipid carriers for topical delivery: preparation, characterisation and ex vivo investigation
The present work is designed to achieve efficient localized skin delivery of folic acid (FA) loaded nanostructured lipid carriers (NLCs) to infer efficient treatment of skin photoaging conditions induced via excessive exposure to ultraviolet (UV) radiation. FA NLCs were prepared by high speed homogenization followed by ultrasonication. The obtained NLCs revealed high encapsulation efficiencies (89.42–99.26%) with nanometric particle sizes (27.06-85.36 nm) of monodisperse distribution (PDI =0.137–0.442), zeta potential values > |27| mV, pseudoplastic rheological behavior, good spreadability (2.25-3.30 cm) and promoted occlusive properties throughout 48 h. Optimized NLC formulations appeared as sphere-shaped particles using transmission electron microscopy, showed improved photostability of FA and prolonged in vitro release profile best fitted to Higuchi diffusion model. Ex vivo permeation and deposition of FA, employing Wistar rat skins, depicted enhanced permeability and existence of FA in skin layers after 6 h. Based on the obtained results, FA loaded NLC formulations demonstrate a promising modality for anti-photoaging therapy.
- 7 May 2020
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 37 (5) , 366-383
Development of folic acid–loaded nanostructured lipid carriers for topical delivery: preparation, characterisation and ex vivo investigation
The present work is designed to achieve efficient localized skin delivery of folic acid (FA) loaded nanostructured lipid carriers (NLCs) to infer efficient treatment of skin photoaging conditions induced via excessive exposure to ultraviolet (UV) radiation. FA NLCs were prepared by high speed homogenization followed by ultrasonication. The obtained NLCs revealed high encapsulation efficiencies (89.42–99.26%) with nanometric particle sizes (27.06-85.36 nm) of monodisperse distribution (PDI =0.137–0.442), zeta potential values > |27| mV, pseudoplastic rheological behavior, good spreadability (2.25-3.30 cm) and promoted occlusive properties throughout 48 h. Optimized NLC formulations appeared as sphere-shaped particles using transmission electron microscopy, showed improved photostability of FA and prolonged in vitro release profile best fitted to Higuchi diffusion model. Ex vivo permeation and deposition of FA, employing Wistar rat skins, depicted enhanced permeability and existence of FA in skin layers after 6 h. Based on the obtained results, FA loaded NLC formulations demonstrate a promising modality for anti-photoaging therapy.